NeuroOne Medical Technologies (NASDAQ:NMTC) Now Covered by Analysts at Maxim Group

Maxim Group started coverage on shares of NeuroOne Medical Technologies (NASDAQ:NMTC) in a report issued on Tuesday,Benzinga reports. The brokerage issued a buy rating and a $3.00 target price on the stock.

NeuroOne Medical Technologies Stock Performance

Shares of NMTC stock opened at $0.89 on Tuesday. NeuroOne Medical Technologies has a one year low of $0.40 and a one year high of $1.39. The company has a 50 day moving average price of $0.79 and a 200 day moving average price of $0.75. The firm has a market capitalization of $44.68 million, a price-to-earnings ratio of -5.96 and a beta of 0.68.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02. NeuroOne Medical Technologies had a negative net margin of 55.44% and a negative return on equity of 163.49%. The company had revenue of $1.70 million during the quarter, compared to the consensus estimate of $1.82 million. NeuroOne Medical Technologies has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Institutional investors have recently bought and sold shares of the business. Warberg Asset Management LLC purchased a new stake in NeuroOne Medical Technologies during the second quarter worth approximately $27,000. Jane Street Group LLC purchased a new stake in NeuroOne Medical Technologies during the fourth quarter worth approximately $33,000. XTX Topco Ltd purchased a new position in shares of NeuroOne Medical Technologies in the second quarter valued at $51,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of NeuroOne Medical Technologies in the first quarter valued at $69,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of NeuroOne Medical Technologies in the first quarter valued at $84,000. 16.07% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.